Abstract:Marek's disease virus (MDV) is a highly contagious pathogen that causes neoplastic disease, named as Marek's disease (MD). Although it was first described as polyneuritis disease, MD also induces severe immunosuppression and tumors in infected chickens. Based on biological characteristics, MDV is classified into three serotypes. MDV-1 belonging to serotype 1, includes pathogenic strains and their derivatives. Serotype 2 (MDV-2) and 3 (MDV-2) are non-pathogenic strains, usually used as vaccines. Pathogenic MDV-1 is categorized into four pathotypes: Mild virulent (m), virulent (v), very virulent (vv), and very virulent plus (vv+). MD is the first neoplastic disease that has been successfully controlled by vaccine. By using vaccines, the morbidities and mortalities of chickens were significantly reduced in the farm. However, MDV continues to evolve, and more virulent strains have gradually been seen to break through vaccinal immunity, which results in outbreak of disease. In recent years, highly virulent strains have been isolated in the world, becoming a new threat for the control of MD.The natural route of MDV infection is through inhalation of airborne cell-free virus particles from the contaminated dust and dander. Once the virus is inhaled, lung epithelial cells and macrophages are speculated to be the primary target cells for MDV infection. Then the virus infects and amplifies in B cells of lymphoid organs (early cytolytic infection). Finally, T cells, mainly activated CD4(+) T cells are recruited to the lymphoid organs and become latently infected (latency, followed by late cytolytic infection) and therefore transformed (transformation). Reactivation (late cytolytic infection) describes the recurrence of cytolytic replication in response to intra- and/or extracellular stimuli. MDV encodes more than 100 genes. Among them, meq is an oncogenic gene that is unique to MDV-1 and consistently expressed in all MD lymphomas and cell lines. Deletion of the meq gene completely abrogates the tumorigenesis induced by virulent strains, however, still maintains the ability to induce lymphoid organ atrophy. The meq-deleted viral strain could not be used as vaccine even though possessing superior protection advantages. To overcome the disadvantage and improve the safety and usefulness of meqdeleted vaccine strain, in an earlier study, we generated a meq and lorf9 deletion mutant virus as a vaccine candidate. It is important to know if the double-gene deletion vaccine strain still maintains the ability of reactivation and amplification in late cytolytic infectious stage, which may cause more viruses shedding into the environment. To test this hypothesis, Realtime PCR technology was used for quantitative analysis, by detecting MDV-specific ICP4 and chicken OVO genes. Viral content was measured from splenocytes and feather follicle of 63-days old infected chickens. Standard curves were established in the first step, and then total DNA was extracted. CT values were obtained both for ICP4 and OVO genes. Viral copy number per lymphocyte was calculated using the standard curve. The results indicate that the double-gene deletion mutant virus showed significantly reduced replication during latent and reactivation stages. This will be the theoretical basis for further analysis of immunological mechanism induced by the double-gene deletion mutant virus.

An Anti-Tumor Vaccine Against Marek's Disease Virus Induces Differential Activation and Memory Response of æ T Cells and CD8 T Cells in Chickens

Revisiting cellular immune response to oncogenic Marek’s disease virus: the rising of avian T-cell immunity

A Marek's Disease Virus Messenger RNA-Based Vaccine Modulates Local and Systemic Immune Responses in Chickens

Fully Attenuated Meq and Pp38 Double Gene Deletion Mutant Virus Confers Superior Immunological Protection Against Highly Virulent Marek’s Disease Virus Infection

Characterization of Dynamic UbR-Proteasome Subcomplexes by In vivo Cross-linking (X) Assisted Bimolecular Tandem Affinity Purification (XBAP) and Label-free Quantitation*

Immune escape of avian oncogenic Marek's disease herpesvirus and antagonistic host immune responses

Regulation of Wnt/β-catenin signaling by Marek's disease virus in vitro and in vivo

Latest Insights into Marek’s Disease Virus Pathogenesis and Tumorigenesis

Transcriptional Analysis Of Host Responses To Marek'S Disease Virus Infection In Chicken Thymus

Absolute quantification of a very virulent Marek's disease virus dynamic quantity and distributions in different tissues.

Meq And Lorf9 Deletion Significantly Reduced Capacity Of Replication Of Very Virulent Marek'S Disease Virus

Critical Roles of Non-Coding RNAs in Lifecycle and Biology of Marek’s Disease Herpesvirus

The Ectopic Expression of Survivin T34A and FilC Can Enhance the Oncolytic Effects of Vaccinia Virus in Murine Gastric Cancer

Surface-Active Factors in the Efficacy of Chlorhexidine Against Plaque

Marek's Disease Virus Type 1 Encoded Analog of Mir-155 Promotes Proliferation of Chicken Embryo Fibroblast and DF-1 Cells by Targeting Hnrnpab.

Temporal Dynamics of Purinergic Receptor Expression in the Lungs of Marek's Disease (MD) Virus-Infected Chickens Resistant or Susceptible to MD

Lentivector Prime and Vaccinia Virus Vector Boost Generate High-Quality Cd8 Memory T Cells and Prevent Autochthonous Mouse Melanoma

Dynamic Changes in the Splenic Transcriptome of Chickens during the Early Infection and Progress of Marek’s Disease

Expression Profiles Of Micrornas Encoded By The Oncogenic Marek'S Disease Virus Reveal Two Distinct Expression Patterns In Vivo During Different Phases Of Disease

A New Strategy for Efficient Screening and Identification of Monoclonal Antibodies against Oncogenic Avian Herpesvirus Utilizing CRISPR/Cas9-Based Gene-Editing Technology

Integrated analysis of lncRNA and mRNA repertoires in Marek's disease infected spleens identifies genes relevant to resistance